| R20: As a rule, tissue banking should be considered as an option in every clinical trial. |
| R21: The need for biomarker application and the possibility of using trials for biomarker validation should be taken into account in the statistical and logistical design of the trial. |
| R22: Pathologists should be involved in trial design. |
| R23: There should be a comprehensive registry in the tissue bank (ideally coupled to an institutional clinical trial registry system) of the tissue samples collected in the context of clinical trials. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.